Published in J Acquir Immune Defic Syndr on August 15, 2016
Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action. J Acquir Immune Defic Syndr (2016) 0.80
Young Transgender Women's Attitudes Toward HIV Pre-exposure Prophylaxis. J Adolesc Health (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (2015) 9.40
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis (2012) 7.12
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav (2007) 6.19
HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health intervention. Am J Public Health (2001) 6.16
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis (2014) 5.59
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2009) 4.04
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med (2016) 2.86
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol (1999) 1.84
High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr (2011) 1.74
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med (2015) 1.61
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV (2015) 1.31
Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses (2012) 1.23
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis (2011) 1.18
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One (2012) 1.12
Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man. Clin Pharmacol Ther (1977) 1.07
Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy (2009) 1.01
Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res (2000) 1.00
Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev (2005) 0.98
Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties. Antiviral Res (2010) 0.96
Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. AIDS (2014) 0.96
Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol (2014) 0.95
Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission. PLoS One (2014) 0.93
Safety of hormonal treatment in transgenders. Curr Opin Endocrinol Diabetes Obes (2013) 0.91
Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther (2013) 0.91
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol (2011) 0.91
The importance of oestrogens in males. Clin Endocrinol (Oxf) (2003) 0.91
Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques. J Acquir Immune Defic Syndr (2014) 0.90
Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture. PLoS One (2014) 0.88
Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception (2013) 0.88
Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology (2011) 0.87
Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women. J Clin Pharmacol (2015) 0.86
Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. Curr Opin HIV AIDS (2008) 0.86
Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner. EBioMedicine (2015) 0.86
Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas (1982) 0.86
Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos (2005) 0.83
Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro. J Antimicrob Chemother (2008) 0.82
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. Expert Opin Drug Metab Toxicol (2015) 0.82
Sex differences in HIV-1-mediated immunopathology. Curr Opin HIV AIDS (2016) 0.81
Role and modulation of drug transporters in HIV-1 therapy. Adv Drug Deliv Rev (2016) 0.78
Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica (2016) 0.77
Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives. J Exp Pharmacol (2013) 0.76
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal (2013) 1.11
Engagement-in-care during the first 5 years after HIV diagnosis: data from a cohort of newly HIV-diagnosed individuals in a large US city. AIDS Patient Care STDS (2014) 0.80